Commission Delegated Regulation (EU) 2024/2564 of 19 June 2024 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances
Date: 2024-06-19
Institutions: Directorate-General for Environment, European Commission
Subjects: classification, dangerous substance, environmental protection, harmonisation of standards, labelling, packaging, public health








L_202402564EN.000101.fmx.xml












Official Journal of the European Union


EN
L series













2024/2564


30.9.2024







            COMMISSION DELEGATED REGULATION (EU) 2024/2564
of 19 June 2024
         
amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances
(Text with EEA relevance)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:







(1)


Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.












(2)


Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘the Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment (RAC) of the Agency adopted, after having taken account of the comments received from the parties concerned, the following opinions (2) on those proposals:






—


Opinion of 18 March 2022 concerning multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T;










—


Opinion of 18 March 2022 concerning α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde;
(2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3];










—


Opinion of 18 March 2022 concerning acetone oxime;










—


Opinion of 18 March 2022 concerning (3E)-dec-3-en-2-one;










—


Opinion of 18 March 2022 concerning 2,3-epoxypropyl neodecanoate;










—


Opinion of 18 March 2022 concerning propyl 3,4,5-trihydroxybenzoate;










—


Opinion of 18 March 2022 concerning benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate;










—


Opinion of 18 March 2022 concerning hexyl salicylate;










—


Opinion of 18 March 2022 concerning sulfur;










—


Opinion of 18 March 2022 concerning reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2];










—


Opinion of 18 March 2022 concerning 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol;










—


Opinion of 30 May 2022 concerning glyphosate (ISO); N-(phosphonomethyl)glycine;










—


Opinion of 2 June 2022 concerning silver massive: [particle diameter ≥ 1 mm];










—


Opinion of 2 June 2022 concerning silver powder: [particle diameter > 100 nm < 1 mm];










—


Opinion of 2 June 2022 concerning silver nano: [particle diameter > 1 nm ≤ 100 nm];










—


Opinion of 2 June 2022 concerning S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (R
a
S
a)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide];










—


Opinion of 2 June 2022 concerning 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one;










—


Opinion of 2 June 2022 concerning formaldehyde … %;










—


Opinion of 2 June 2022 concerning formic acid … %;










—


Opinion of 2 June 2022 concerning dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid;










—


Opinion of 2 June 2022 concerning 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate;










—


Opinion of 2 June 2022 concerning peracetic acid … %;










—


Opinion of 2 June 2022 concerning tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy) ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotised 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3];










—


Opinion of 15 September 2022 concerning perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5];










—


Opinion of 15 September 2022 concerning perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4]










—


Opinion of 15 September 2022 concerning sodium peroxometaborate;










—


Opinion of 15 September 2022 concerning trimethyl borate;










—


Opinion of 15 September 2022 concerning ethanethiol;
ethyl mercaptan;










—


Opinion of 15 September 2022 concerning 1H-benzotriazole;










—


Opinion of 15 September 2022 concerning methyl-1H-benzotriazole;










—


Opinion of 15 September 2022 concerning N,N'-methylenediacrylamide;










—


Opinion of 15 September 2022 concerning Sodium 3-(allyloxy)-2-hydroxypropanesulphonate;










—


Opinion of 1 December 2022 concerning tert-butyl 2-ethylperoxyhexanoate;










—


Opinion of 1 December 2022 concerning n-hexane;










—


Opinion of 1 December 2022 concerning biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl;










—


Opinion of 1 December 2022 concerning copper [specific surface area > 0,67 mm2/mg];










—


Opinion of 1 December 2022 concerning reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol;










—


Opinion of 1 December 2022 concerning 1,4-dichloro-2-nitrobenzene;










—


Opinion of 1 December 2022 concerning 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16];










—


Opinion of 1 December 2022 concerning pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate;










—


Opinion of 1 December 2022 concerning dibenzoyl peroxide; benzoyl peroxide;










—


Opinion of 1 December 2022 concerning fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine.
















(3)


The Commission has received additional information from stakeholders contesting the scientific assessment set out in the RAC opinions of 18 March 2022 concerning benthiavalicarb-isopropyl, 2,3-epoxypropyl neodecanoate, multi-walled carbon tubes, hexyl salicylate, in the RAC opinions of 2 June 2022 concerning silver massive, silver powder and silver nano and in the RAC opinions of 1 December 2022 concerning n-hexane and copper. The additional information has been assessed by the Commission and has not been found sufficient to cast doubts on the scientific analysis contained in the RAC opinions.












(4)


With regard to the substance copper flakes (coated with aliphatic acid) (index number 029-019-01-X (3)), its entry for its classification as hazardous for the aquatic environment should be amended to be in accordance with the more generic entry copper [specific surface area > 0,67 mm2/mg] (index number 029-026-00-0), inserted in the Annex.












(5)


With regard to the substance granulated copper (4) (index number 029-024-00-X), its entry should be deleted as it is covered by the more generic entry copper [specific surface area > 0,67 mm2/mg] (index number 029-026-00-0), inserted in the Annex.












(6)


Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessment, an ATE value for the inhalation route has been derived for fenpropidin (index number 612-299-00-0), in addition to those proposed in the RAC opinions for other substances. That ATE value should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008.












(7)


The entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 have been replaced by the entries for perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5] (index number 005-022-00-4), for perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] (index number 005-023-00-X) and for sodium peroxometaborate (index number 005-024-00-5) and should therefore be deleted.












(8)


In light of the RAC opinions, it is appropriate to introduce, update or delete the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions and following the further assessments.












(9)


Regulation (EC) No 1272/2008 should therefore be amended accordingly.












(10)


Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,





HAS ADOPTED THIS REGULATION:



Article 1
Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.


Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 May 2026 However, substances and mixtures may be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation from the date of entry into force of this Regulation.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 19 June 2024.


For the Commission


The President

Ursula VON DER LEYEN
            





(1)  
            OJ L 353, 31.12.2008, p. 1, ELI: http://data.europa.eu/eli/reg/2008/1272/oj.

(2)  The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/.

(3)  See RAC Opinion of 1 December 2022 concerning copper [specific surface area > 0,67 mm2/mg], listed above;

(4)  Ibidem.




ANNEX
Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:






(1)


the following entries are inserted following the consecutive order of the index numbers corresponding to each entry:















Index No


Chemical Name


EC No


CAS No


Classification


Labelling


Specific Conc. Limits, M-factors and ATE


Notes




Hazard Class and Category Code(s)


Hazard statement Code(s)


Pictogram, Signal Word Code(s)


Hazard statement Code(s)


Suppl. Hazard statement Code(s)




‘005-022-00-4


perboric acid, sodium salt [1]
perboric acid, sodium salt, monohydrate [2]
perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4]
sodium perborate [5]


234-390-0 [1]
234-390-0 [2]
- [3]
- [4]
239-172-9 [5]


11138-47-9 [1]
12040-72-1 [2]
10332-33-9 [3]
- [4]
15120-21-5 [5]


Ox. Sol. 3
Repr. 1B
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Dam. 1


H272
H360FD
H331
H302
H335
H318


GHS03
GHS08
GHS06
GHS05
Dgr


H272
H360FD
H331
H302
H335
H318


 


inhalation: ATE = 0,75 mg/L (dusts or mists)
oral: ATE = 890 mg/kg bw
Eye Dam. 1; H318:
C ≥ 22 %
Eye Irrit. 2; H319:
14 % ≤ C < 22 %


11’




‘005-023-00-X


perboric acid (H3BO2(O2)), monosodium salt trihydrate [1]
perboric acid, sodium salt, tetrahydrate [2]
perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4]


239-172-9 [1]
234-390-0 [2]
- [3]
- [4]


13517-20-9 [1]
37244-98-7 [2]
10486-00-7 [3]
- [4]


Repr. 1B
Acute Tox. 4
STOT SE 3
Eye Dam. 1


H360FD
H332
H335
H318


GHS08
GHS05
GHS07
Dgr


H360FD
H332
H335
H318


 


inhalation: ATE = 1,2 mg/L (dusts or mists)
Eye Dam. 1; H318: C ≥ 36 %
Eye Irrit. 2; H319: 22 % ≤ C < 36 %


11’




‘005-024-00-5


sodium peroxometaborate


231-556-4


7632-04-4


Ox. Sol. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Dam. 1


H272
H360FD
H331
H302
H335
H318


GHS03
GHS08
GHS06
GHS05
Dgr


H272
H360FD
H331
H302
H335
H318


 


inhalation: ATE = 0,62 mg/L (dusts or mists)
oral: ATE = 730 mg/kg bw
Eye Dam. 1; H318:
C ≥ 22 %
Eye Irrit. 2; H319: 14 % ≤ C < 22 %


11’




‘006-104-00-2


multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T


—


—


Carc. 1B
STOT RE 1


H350i
H372 (lung)(inhalation)


GHS08
Dgr


H350i
H372 (lung)(inhalation)


 


STOT RE 1; H372: C ≥ 1 %;
STOT RE 2; H373: 0,1 % ≤ C < 1 %’


 




‘029-026-00-0


copper [specific surface area > 0,67 mm2/mg]


231-159-6


7440-50-8


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 10
M = 1’


 




‘047-004-00-9


silver massive: [particle diameter ≥ 1 mm]


231-131-3


7440-22-4


Repr. 2
STOT RE 2


H361f
H373 (nervous system)


GHS08
Wng


H361f
H373 (nervous system)’


 


 


 




‘047-005-00-4


silver powder: [particle diameter > 100 nm < 1 mm]


231-131-3


7440-22-4


Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H361f
H373 (nervous system)
H400
H410


GHS08
GHS09
Wng


H361f
H373 (nervous system)
H410


 


M = 10
M = 10’


 




‘047-006-00-X


silver nano: [particle diameter > 1 nm ≤ 100 nm]


231-131-3


7440-22-4


Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H361f
H373 (nervous system)
H400
H410


GHS08
GHS09
Wng


H361f
H373 (nervous system)
H410


 


M = 1 000 
M = 1 000 ’


 




‘603-247-00-8


reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol


—


—


Repr. 1B


H360Df


GHS08
Dgr


H360Df’


 


 


 




‘605-042-00-9


α-methyl-1,3-benzodioxole-5-propionaldehyde [1]
(S)-α-methyl-1,3-benzodioxole-5-propionaldehyde;
(2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2]
(R)-α-methyl-1,3-benzodioxole-5-propionaldehyde;
(2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3]


214-881-6 [1]
- [2]
- [3]


1205-17-0 [1]
737776-68-0 [2]
737776-59-9 [3]


Skin Sens. 1B


H317


GHS07
Wng


H317’


 


 


 




‘605-043-00-4


2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1]
(1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2]
2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3]
3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4]
3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5]
4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6]
reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7]
dimethylcyclohex-3-ene-1-carbaldehyde [8]
Dimethylcyclohex-3-ene-1-carbaldehyde [9]
1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10]
1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11]
2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12]
2,4,6-trimethylcyclohex-3-enecarbaldehyde [13]
isocyclocitral [14]
3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15]
4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16]


268-264-1 [1]
252-395-6 [2]
- [3]
268-263-6 [4]
267-186-5 [5]
253-139-6 [6]
- [7]
248-742-6 [8]
272-113-5 [9]
276-055-1 [10]
- [11]
- [12]
215-833-7 [13]
215-638-7 [14]
266-810-3 [15]
- [16]


68039-49-6 [1]
35145-02-9 [2]
6975-94-6 [3]
68039-48-5 [4]
67801-65-4 [5]
36635-35-5 [6]
- [7]
27939-60-2 [8]
68737-61-1 [9]
71832-78-5 [10]
40702-26-9 [11]
1726-47-2 [12]
1423-46-7 [13]
1335-66-6 [14]
67634-07-5 [15]
6754-27-4 [16]


Skin Sens. 1


H317


GHS07
Wng


H317’


 


 


 




‘606-156-00-1


acetone oxime


204-820-1


127-06-0


Carc. 1B
Acute Tox. 4
STOT SE 3
STOT RE 2
Eye Dam. 1
Skin Sens. 1


H350
H312
H336
H373 (blood system)
H318
H317


GHS08
GHS07
GHS05
Dgr


H350
H312
H336
H373 (blood system)
H318
H317


 


dermal: ATE = 1 100  mg/kg bw’


 




‘606-157-00-7


(3E)-dec-3-en-2-one


—


18402-84-1


Acute Tox. 4
Asp. Tox. 1
Skin Irrit. 2
Aquatic Chronic 2


H332
H304
H315
H411


GHS07
GHS08
GHS09
Dgr


H332
H304
H315
H411


EUH071


inhalation: ATE = 1,5 mg/L (dusts or mists)’


 




‘606-158-00-2


2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one


438-340-0


119344-86-4


Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1


H360Df
H400
H410


GHS08
GHS09
Dgr


H360Df
H410


 


M = 1
M = 1’


 




‘607-770-00-2


2,3-epoxypropyl neodecanoate


247-979-2


26761-45-5


Muta. 2
Skin Sens. 1A


H341
H317


GHS08
GHS07
Wng


H341
H317


 


Skin Sens. 1A; H317: C ≥ 0,001 %’


 




‘607-771-00-8


benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate


—


177406-68-7


Carc. 1B
Repr. 2
Skin Sens. 1
Aquatic Chronic 2


H350
H361fd
H317
H411


GHS08
GHS07
GHS09
Dgr


H350
H361fd
H317
H411’


 


 


 




‘607-772-00-3


hexyl salicylate


228-408-6


6259-76-3


Repr. 2
Skin Sens. 1


H361d
H317


GHS08
GHS07
Wng


H361d
H317’


 


 


 




‘607-773-00-9


7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate


219-207-4


2386-87-0


Muta. 2
STOT RE 2
Skin Sens. 1


H341
H373 (nasal cavity)
H317


GHS08
GHS07
Wng


H341
H373 (nasal cavity)
H317’


 


 


 




‘607-774-00-4


tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1]
Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2]
disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3]


241-164-5 [1]
- [2]
- [3]


17095-24-8 [1]
- [2]
100556-82-9 [3]


Resp. Sens. 1A
Skin Sens. 1


H334
H317


GHS08
Dgr


H334
H317’


 


 


 




‘607-775-00-X


Sodium 3-(allyloxy)-2-hydroxypropanesulphonate


258-004-5


52556-42-0


Repr. 1B
Eye Dam. 1


H360F
H318


GHS08
GHS05
Dgr


H360F
H318’


 


 


 




‘609-074-00-4


1,4-dichloro-2-nitrobenzene


201-923-3


89-61-2


Carc. 1B


H350


GHS08
Dgr


H350’


 


 


 




‘611-182-00-1


2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol


271-183-4


68516-81-4


Skin Sens. 1A


H317


GHS07
Wng


H317


 


Skin Sens. 1A; H317: C ≥ 0,001 %’


 




‘612-299-00-0


fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine


—


67306-00-7


Repr. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT SE 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H361d
H332
H302
H335
H336
H373 (nervous system, eyes, lungs)
H315
H318
H317
H400
H410


GHS08
GHS07
GHS05
GHS09
Dgr


H361d
H332
H302
H335
H336
H373 (nervous system, eyes, lungs)
H315
H318
H317
H410


 


Inhalation: ATE = 1,2 mg/L (dusts or mists)
oral: ATE = 1 330  mg/kg bw
M = 1 000 
M = 10 000 ’


 




‘613-350-00-X


1H-benzotriazole


202-394-1


95-14-7


Aquatic Chronic 2


H411


GHS09
Wng


H411’


 


 


 




‘613-351-00-5


methyl-1H-benzotriazole


249-596-6


29385-43-1


Aquatic Chronic 2


H411


GHS09
Wng


H411’


 


 


 




‘616-243-00-6



N,N'-methylenediacrylamide


203-750-9


110-26-9


Muta. 1B


H340


GHS08
Dgr


H340’


 


 


 




‘617-024-00-8



tert-butyl 2-ethylperoxyhexanoate


221-110-7


3006-82-4


Repr. 1B
Skin Sens. 1


H360FD
H317


GHS08
GHS07
Dgr


H360FD
H317’


 


 


 














(2)


the entries corresponding to index numbers 005-005-00-1, 016-022-00-9, 016-094-00-1, 029-019-01-X, 601-037-00-0, 604-020-00-6, 605-001-00-5, 607-001-00-0, 607-043-00-X, 607-094-00-8, 607-198-00-3, 607-315-00-8, 607-432-00-4, 613-272-00-6, 616-127-00-5 and 617-008-00-0 are replaced by the following entries respectively:















Index No


Chemical Name


EC No


CAS No


Classification


Labelling


Specific Conc. Limits, M-factors and ATE


Notes




Hazard Class and Category Code(s)


Hazard statement Code(s)


Pictogram, Signal Word Code(s)


Hazard statement Code(s)


Suppl. Hazard statement Code(s)




‘005-005-00-1


trimethyl borate


204-468-9


121-43-7


Flam. Liq. 3
Repr. 1B
Acute Tox. 4*


H226
H360FD
H312


GHS02
GHS08
GHS07
Dgr


H226
H360FD
H312


 


 


11’




‘016-022-00-9


ethanethiol;
ethyl mercaptan


200-837-3


75-08-1


Flam. Liq. 1
Acute Tox. 3
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H224
H331
H302
H400
H410


GHS02
GHS06
GHS09
Dgr


H224
H331
H302
H410


 


inhalation: ATE = 7,1 mg/L (vapours)
oral: ATE = 680 mg/kg bw’


 




‘016-094-00-1


sulfur


231-722-6


7704-34-9


Skin Irrit. 2


H315


GHS07
Wng


H315’


 


 


 




‘029-019-01-X


copper flakes (coated with aliphatic acid)


 


 


Acute Tox. 3 Acute Tox. 4
Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1


H331
H302
H319
H400
H410


GHS06
GHS09
Dgr


H331
H302
H319
H410


 


inhalation: ATE = 0,733 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 1’


 




‘601-037-00-0



n-hexane


203-777-6


110-54-3


Flam. Liq. 2
Repr. 2
Asp. Tox. 1
STOT SE 3
STOT RE 1
Skin Irrit. 2
Aquatic Chronic 2


H225
H361f***
H304
H336
H372 (nervous system)
H315
H411


GHS02
GHS08
GHS07
GHS09
Dgr


H225
H361f***
H304
H336
H372 (nervous system)
H315
H411’


 


 


 




‘604-020-00-6


biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl


201-993-5


90-43-7


Carc. 2
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1


H351
H314
H318
H317
H400
H410


GHS08
GHS05
GHS07
GHS09
Dgr


H351
H314
H317
H410


 


M = 1
M = 1’


 




‘605-001-00-5


formaldehyde … %


200-001-8


50-00-0


Carc. 1B
Muta. 2
Acute Tox. 2
Acute Tox. 4
Skin Corr. 1B
Skin Sens. 1A


H350
H341
H330
H302
H314
H317


GHS08
GHS06
GHS05
Dgr


H350
H341
H330
H302
H314
H317


EUH071


inhalation: ATE = 100 ppmV (gases)
oral: ATE = 500 mg/kg bw
STOT SE 3; H335: C ≥ 5 %
Skin Corr. 1B; H314: C ≥ 25 %
Skin Irrit. 2; H315: 5 % ≤ C < 25 %
Eye Irrit. 2; H319: 5 % ≤ C < 25 %


B, D, F’




‘607-001-00-0


formic acid … %


200-579-1


64-18-6


Flam. Liq. 3
Met. Corr. 1
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1A
Eye Dam. 1


H226
H290
H331
H302
H314
H318


GHS02
GHS05
GHS06
Dgr


H226
H290
H331
H302
H314


EUH071


inhalation: ATE = 7,4 mg/L (vapours)
oral: ATE = 500 mg/kg bw
Flam. Liq. 3; H226: C > 85 %
Skin Corr. 1A; H314: C ≥ 90 %
Skin Corr. 1B; 314: 10 % ≤ C < 90 %
Skin Irrit. 2; H315: 2 % ≤ C < 10 %
Eye Dam. 1; H318: C ≥ 10 %
Eye Irrit. 2; H319: 2 % ≤ C < 10 %


B’




‘607-043-00-X


dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid


217-635-6


1918-00-9


Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT SE 3
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 2


H332
H302
H335
H336
H318
H400
H411


GHS07
GHS05
GHS09
Dgr


H332
H302
H335
H336
H318
H410


 


inhalation: ATE = 4,0 mg/L (dusts or mists)
oral: ATE = 1 500  mg/kg bw
M = 1’


 




‘607-094-00-8


peracetic acid … %


201-186-8


79-21-0


Org. Perox. D
Acute Tox. 2
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1A
Aquatic Acute 1
Aquatic Chronic 1


H242
H330
H310
H301
H314
H400
H410


GHS02
GHS06
GHS05
GHS09
Dgr


H242
H330
H310
H301
H314
H410


EUH071


inhalation: ATE = 0,2 mg/L (dusts or mists)
dermal: ATE = 60 mg/kg bw
oral: ATE = 80 mg/kg bw
STOT SE 3; H335: C ≥ 1 %
M = 10
M = 100


B, D, T’




‘607-198-00-3


propyl 3,4,5-trihydroxybenzoate


204-498-2


121-79-9


Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H302
H317
H400
H410


GHS07
GHS09
Wng


H302
H317
H410


 


oral: ATE = 1 700  mg/kg bw
M = 1
M = 1’


 




‘607-315-00-8


glyphosate (ISO); N-(phosphonomethyl)glycine


213-997-4


1071-83-6


Eye Dam. 1
Aquatic Chronic 2


H318
H411


GHS05
GHS09
Dgr


H318
H411’


 


 


 




‘607-432-00-4



S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (R
a
S
a)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide
[contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide]


—


87392-12-9


Carc. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H317
H410


EUH066


M = 10
M = 10’


 




‘613-272-00-6


pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate


—


175013-18-0


Repr. 2
Acute Tox. 3
Acute Tox. 4
STOT SE 3
STOT RE 2
Skin Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H331
H302
H335
H373 (liver, gastrointestinal tract, nasal cavity)
H315
H400
H410


GHS08
GHS06
GHS09
Dgr


H361d
H331
H302
H335
H373 (liver, gastrointestinal tract, nasal cavity)
H315
H410


 


inhalation: ATE = 0,58 mg/L (dusts or mists)
oral: ATE = 450 mg/kg bw
M = 100
M = 100’


 




‘616-127-00-5


reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1]
reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2]


430-050-2 [1]
- [2]


- [1]
- [2]


Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H317
H400
H410


GHS07
GHS09
Wng


H317
H410


 


M = 100
M = 10’


 




‘617-008-00-0


dibenzoyl peroxide; benzoyl peroxide


202-327-6


94-36-0


Org. Perox. B
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H241
H319
H317
H400
H410


GHS01
GHS02
GHS07
GHS09
Dgr


H241
H319
H317
H410


 


M = 10
M = 10’


 














(3)


the entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 and 029-024-00-X are deleted.







ELI: http://data.europa.eu/eli/reg_del/2024/2564/oj
ISSN 1977-0677 (electronic edition)